Extract
Chronic cough is a common and troublesome clinical problem and currently there are no effective treatments [1]. While individual specialist cough clinics have been set up in some European countries, there is no formal mechanism to develop common management approaches. Furthermore, the vast majority of clinical trials of novel anti-tussive treatment have been conducted in a limited number of sites in the UK and USA, with little in the way of cough clinical trial infrastructure across Europe [2–7]. The NEw Understanding in the tReatment Of COUGH (NEUROCOUGH) Clinical Research Collaboration (CRC) seeks to address this through creating a platform allowing clinicians, together with researchers in academia and industrial partners across Europe and beyond, to exchange ideas and facilitate collaborations geared towards improved care and treatment for patients with cough. The core aims of NEUROCOUGH are to: 1) create a registry of Europe-wide specialist cough clinics operating according to agreed and standardised protocols; 2) establish a Europe-wide registry of “clinical trial ready” chronic cough patients suitable for multicentre experimental medicine studies and later phase precision medicine clinical trials; 3) seek public engagement to provide input into NEUROCOUGH based on the priorities and unmet needs of patients; and 4) encourage early career researchers and clinicians into the field of cough.
Abstract
The NEUROCOUGH ERS Clinical Research Collaboration brings together clinicians, scientists, patients and industry from Europe and beyond, with a focus on improving care and treatment for patients with chronic cough http://bit.ly/2Q6l0ER
Acknowledgements
We are grateful to Elise Heuvelin, Celine Genton and Steve Sealy from the European Respiratory Society executive office (Lausanne, Switzerland) for their logistical support for NEUROCOUGH. We thank Tracie Andreasson (Queen's University Belfast, Belfast, UK) for clerical support.
Footnotes
Members of the NEUROCOUGH Clinical Research Collaboration are as follows. Chair: Lorcan McGarvey; co-chair: Lieven Dupont. National Leads: Surinder S. Birring (UK), Kian Fan Chung (UK), Marta Dabrowska (Poland), Christian Domingo (Spain), Giovanni Fontana (Italy), Laurent Guilleminault (France), Peter Kardos (Germany), Eva Millqvist (Sweden), Alyn H. Morice (UK), Jaclyn A. Smith (UK) and Jan Willem van den Berg (the Netherlands). Early Career Member: Charlotte Van de Kerkhove (Belgium). European Lung Foundation: Courtney Coleman and Jeanette Boyd. International Advisory Board: Ian Adcock (UK), Peter Dicpinigaitis (USA), Piero Geppetti (Italy), Peter Gibson (Australia), Kefang Lai (China), Stuart Mazzone (Australia), Clive Page (UK), Ian Pavord (UK) and Woo-Jung Song (South Korea).
Conflict of interest: L. McGarvey reports grants from European Union Interreg VA Health and Life Science Programme, NC3R, Chiesi, Boehringer Ingelheim and GlaxoSmithKline; personal fees (including for advisory boards) from Merck and Co., Inc., Sanofi and Bellus Health; and non-financial support from Chiesi, Boehringer Ingelheim and GlaxoSmithKline, all during the conduct of the study.
Conflict of interest: L. Dupont has nothing to disclose.
Conflict of interest: S.S. Birring reports grants from Merck, and personal fees (for scientific advisory work) from Merck, Bayer, Respivant, Pfizer and Sanofi, all outside the submitted work.
Conflict of interest: J. Boyd is an employee of the European Lung Foundation.
Conflict of interest: K.F. Chung has received honoraria for participating in advisory board meetings from GlaxoSmithKline, AstraZeneca, Novartis, Boehringer Ingelheim and Teva, regarding treatments for asthma and chronic obstructive pulmonary disease; and has also been renumerated for speaking engagements by AstraZeneca, Novartis and Merck.
Conflict of interest: M. Dabrowska reports personal fees and other support from Angelini Pharma Poland (travel expenses and fees for attendance at ERS International Congresses 2017 and 2018 and at International Symposium on Cough 2018, and fees for lectures) and Chiesi (fees for attendance at ERS Congress 2016 and for lectures), outside the submitted work.
Conflict of interest: C. Domingo reports personal fees (including speaker's honoraria) from ALK, Almirall, Chiesi, Esteve, Ferrer, GSK, Hal Allergy, ImmunoTek, Menarini, Sanofi, Novartis, Stallergenes Greer and Teva; non-financial support from GSK; and other support (including congress fees and advisory board fees) from Allergy Therapeutics, ALK, AstraZeneca, Menarini, Novartis, MSD and Teva, all outside the submitted work.
Conflict of interest: G. Fontana has nothing to disclose.
Conflict of interest: L. Guilleminault reports personal fees and non-financial support from ALK and AstraZeneca (for councils, invitations to congresses and participation in clinical trials) and from Chiesi (for a council and invitation to a congress); non-financial support from Boehringer Ingelheim (for invitation to a congress); personal fees from Bayer and GSK (for councils); other support from MSD (for participation in clinical trials); and personal fees, non-financial support and other support from Novartis (for councils, invitations to congresses and participation in clinical trials), all outside the submitted work.
Conflict of interest: P. Kardos reports personal fees from AstraZeneca, GSK, Menarini, Novartis, Klosterfrau, Bionorica, Willmar Schwabe and MSD, and other support (for a phase 3 investigator cough study) from MSD, all outside the submitted work.
Conflict of interest: E. Millqvist reports a pending user patent application for treatment of chronic cough with oral capsaicin.
Conflict of interest: A.H. Morice reports grants from Merck, Bayer, GSK and Sanofi; and personal fees from Merck, Bayer, Bellus and Sanofi, all outside the submitted work.
Conflict of interest: J.A. Smith reports grants from GlaxoSmithKline, Axalbion and Merck Inc. (funding for a commercial study to Manchester University NHS Foundation Trust), NeRRe Pharmaceuticals (to Christie Hospital, commercial funding for clinical trial), Menlo and Bayer (commercial funding for clinical trial), Afferent (to Manchester University NHS Foundation Trust) and AstraZeneca (contributed funding to MRC MICA grant); personal fees from GlaxoSmithKline and Merck Inc. (for advisory boards and consultancy work), from NeRRe Pharmaceuticals, Menlo, Bayer, Axalbion, AstraZeneca, Boehringer Ingelheim, Genentech, Neomed, Chiesi and Bellus (for consultancy), and from Afferent; and non-financial support from Vitalograph (for provision of cough monitoring equipment), all outside the submitted work. In addition, J.A. Smith is the inventor of a licensed patent “A method for generating output data” (owned by University Hospital of South Manchester, no personal royalties received).
Conflict of interest: J.W. van den Berg reports personal fees and non-financial support (for a one-time advisory panel meeting) from MSD, outside the submitted work.
Conflict of interest: C. Van de Kerkhove has nothing to disclose.
Support statement: J.A. Smith is funded by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre and is an NIHR Senior Investigator.
- Received April 18, 2019.
- Accepted May 5, 2019.
- Copyright ©ERS 2019